UBS Group
INO icon

UBS Group’s Inovio Pharmaceuticals INO Stock Holding History

UBS Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-83
Closed -$8K – 8661
2015
Q1 		$8K Sell
83
-75
-47% -$7.27K ﹤0.01% 7812
2014
Q4 		$17K Buy
+158
New +$19.3K ﹤0.01% 7878

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's INO Position: Q1 2026 in Review

UBS Group increased its Inovio Pharmaceuticals (INO) stake by 46% in Q1 2026, buying an estimated $130K and bringing the position to 249,650 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #6179.

UBS Group first reported a position in INO in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.89M in Q1 2022. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • UBS Group held 249,650 shares of Inovio Pharmaceuticals worth $434K as of Q1 2026.
  • UBS Group bought 79,071 Inovio Pharmaceuticals shares in Q1 2026, an estimated $130K.
  • Inovio Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6179 holding.
  • UBS Group first reported a position in Inovio Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Inovio Pharmaceuticals position peaked at $5.89M in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.